LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Cancer|Melanoma|Breast Cancer|Head and Neck Cancer|Lymphoma|Triple-Negative Breast Cancer
Interventions: DRUG: LTX-315 consecutive lesions|DRUG: LTX-315|DRUG: LTX-315 + ipilimumab|DRUG: LTX-315 + pembrolizumab
Sponsor: Lytix Biopharma AS
Collaborators: Theradex|ICON plc